tradmap

GCTK Glucotrack, Inc.

$0.62 -69.45%

Data as of close

Healthcare · Surgical & Medical Instruments & Apparatus

Glucotrack, Inc. (GCTK) is a healthcare company in the Surgical & Medical Instruments & Apparatus industry, with a market capitalization of $219193. Shares last traded at $0.62, 99.8% below their 52-week high. Over the past year the stock is down 99.7%. Revenue grew 378.3% year over year.

Market Cap
$0M
Shares Out
352,627.4
EPS (TTM)
-$453.90
P/E (TTM)*
—
P/S Ratio
1.05
P/B Ratio
—
Dividend / Share
—
Dividend Yield
—
52-Week High
$249.00
52-Week Low
$0.62
Volume (venue)
68,245
Avg Vol (3m, venue)
25,723.479

* P/E (TTM) = market cap ÷ net income over the trailing twelve months where four consecutive quarters are reported, otherwise the latest fiscal year — the same basis as the peer table and the screener, so it can differ from price ÷ EPS.

Performance

1W
-48.83%
1M
-81.05%
3M
-95.45%
6M
-97.55%
YTD
-99.47%
1Y
-99.69%

Daily candles · volume · SMA(20)/SMA(50) · split-adjusted · Databento EQUS.MINI. GCTK split history →

Technicals

RSI (14)
32.48
SMA (50)
$4.45
SMA (200)
$24.00
Price vs SMA50
-86.04%
Price vs SMA200
-97.41%
ATR (14)
$0.71

Full technical analysis (26 indicators, D/W/M) →

Financials

Revenue
$208000
Net Income
-$16M
Gross Margin
—
Operating Margin
—
Net Margin
—
Return on Equity
916.0%
Return on Assets
-1066.7%
Current Ratio
0.46
Debt / Equity
-1.86
Revenue Growth (YoY)
+378.3%

Trailing twelve months where four consecutive quarters are reported, otherwise the latest fiscal year; revenue is the fiscal-year figure where quarterly revenue covers under half of it (typical for banks, insurers and REITs), and margins are taken on it; latest reported period ends 2026-06-30. Source: SEC EDGAR/XBRL.

Full financials — revenue, cash flow & debt over time →

Recent earnings

PeriodEPS (diluted)Reported
Q2 2026 $22.80 2026-08-14
Q1 2026 $79.50 2026-05-14
Q4 2025 (derived) -$695.40 2026-03-30
FY 2025 $936.60 2026-03-30
Q3 2025 $139.20 2025-11-13
Q2 2025 $288.60 2025-08-14

Q4 marked "derived" = fiscal-year EPS minus Q1–Q3 (10-Ks report only the annual figure); EPS is not strictly additive, so it can differ by a cent or two from the issuer's own Q4.

Full earnings history →

Surgical & Medical Instruments & Apparatus peers

GCTK vs 14 industry peers (Surgical & Medical Instruments & Apparatus), by market cap. Data as of close

P/S vs peers
1.05 / 2.81 med
-62% discount
1–14 of 14
SYKStryker Corporation$116.8B32.254.4413.8%+5.32%
MMM3M$92.2B26.073.6514.0%+2.35%
BSXBoston Scientific$64.3B18.393.0516.6%+5.62%
BDXBecton Dickinson$54.1B57.492.604.5%+0.39%
RMDResMed$32.8B20.565.7127.8%+1.35%
DXCMDexCom$31.6B31.906.1919.4%+2.99%
MDLNMedline Inc.$29.5B—1.04—+4.80%
WSTWest Pharmaceutical Services$28.4B44.468.3618.8%-1.15%
SOLVSolventum$14.4B10.061.7417.3%+4.22%
GKOSGlaukos Corp$14.1B—20.48-24.6%+0.53%
PENPenumbra Inc$12.7B80.679.0211.2%+0.42%
BAXBaxter International$12.5B—1.08-6.2%+5.47%
GMEDGlobus Medical Inc$10.7B19.923.3917.0%+1.81%
PODDInsulet Corporation$10.7B28.393.4912.3%+2.58%

Source: SEC EDGAR (fundamentals/EPS/dividends) · Databento EQUS.MINI (prices) · market cap & yield computed by tradmap. Informational only — not financial advice.